Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on August 1, 2003, to disclose its second quarter 2003 financial results. The report primarily directs investors to a press release, dated August 1, 2003, which contains the detailed financial information and operational updates for the period. This filing serves as the official notification of the company's performance during the second quarter of 2003. Investors are advised to review the attached press release for comprehensive details on Regeneron's financial condition and results of operations. The information provided herein is incorporated by reference into the press release, making it the primary source for understanding the company's performance and outlook as of the reporting date. This 8-K ensures that material financial information is publicly disseminated in a timely manner as required by the SEC.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2003.
- 2The filing discloses the company's second quarter 2003 results of operations and financial condition.
- 3The press release dated August 1, 2003, is the primary document containing the detailed financial information.
- 4The press release is incorporated by reference into the 8-K filing.
- 5This filing fulfills SEC requirements for reporting material financial information.
- 6Investors should consult the referenced press release for specific financial data and operational updates.